What type of study is this?

This is a Human Clinical Trial study.

September 12, 2025Open Access

Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas

Key Points

Mirdametinib significantly alleviates symptoms of plexiform neurofibromas, improving patient quality of life.
In clinical observations, patients treated with mirdametinib experienced reduced tumor size and symptom severity.
This research utilizes targeted therapy approaches to treat NF1-associated plexiform neurofibromas in both adult and pediatric cohorts.
The implications suggest a shift towards personalized medicine in managing neurofibromatosis type 1 patients.

Abstract

INTRODUCTION Neurofibromatosis type 1 (NF1) is an autosomal-dominant cancer predisposition syndrome that leads to the development of plexiform neurofibromas (PNs), which can cause significant morbidity and are at risk to transform into malignant peripheral nerve sheath tumors (MPNSTs). Targeted therapies such as mirdametinib, a selective oral MEK1/2 inhibitor, have offered new treatment options for patients with symptomatic, inoperable PNs.

Read Full Paperexternally

AIに質問

Bookmark

View Full Paper